A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of MLN9708 for the Treatment of Subjects with ISN / RPS Class III or IV Lupus Nephritis Save

Date Added
October 14th, 2014
PRO Number
Pro00036768
Researcher
James C. Oates
Keywords
Lupus
Summary

The purpose of this study is to evaluate the safety and tolerability of an experimental investigational drug called ixazomib (MLN9708) in patients with Lupus Nephritis. This study will compare ixazomib with a placebo to see if taking ixazomib is better than taking a placebo. The study will help to determine how ixazomib behaves inside the body/blood and how it is eliminated from the body. Also, this study will provide information on the effect that ixazomib may have on important characteristics of the lupus nephritis.

Institution
MUSC
Recruitment Contact
Dana Rosson
8437922014
rosson@musc.edu

A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE) Save

Date Added
April 23rd, 2013
PRO Number
Pro00024258
Researcher
James C. Oates
Keywords
Autoimmune disease, Lupus
Summary

EMBRACE is a study of belimumab, also known as BENLYSTA, to treat lupus in adult black women and men. This study is being conducted to see if belimumab works and is safe for black patients. Patients will receive either belimumab or placebo (no drug) once a month in clinic for a year, plus their regular lupus medicines. For more information, contact Abby Powell at 843-792-0549.

Institution
MUSC
Recruitment Contact
Abby Powell
843-792-0549
powab@musc.edu

Change_preferences

-- OR --

Create_login